| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL6R; Interleukin-6 receptor subunit alpha; IL-6 receptor subunit alpha; IL-6R subunit alpha; IL-6R-alpha; IL-6RA; IL-6R 1; Membrane glycoprotein 80; gp80; CD126 |
| Entrez GeneID | 3570; |
| WB Predicted band size | 53kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human IL-6Rα. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IL-6Rα抗体的3篇参考文献，包含标题、作者及摘要概括：
---
1. **标题**: *Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial*
**作者**: RECOVERY Collaborative Group
**摘要**: 这项多中心随机试验评估托珠单抗(IL-6Rα单抗)对COVID-19住院患者的疗效。结果显示，托珠单抗显著降低需吸氧患者的28天死亡率，并减少机械通气需求，尤其在联合糖皮质激素治疗时效果更佳。
2. **标题**: *Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis: a 24-week randomised, placebo-controlled phase III trial*
**作者**: Jones G, et al.
**摘要**: 针对类风湿性关节炎患者的III期临床试验表明，托珠单抗单药治疗较安慰剂显著改善ACR50缓解率(51% vs. 18%)，并抑制关节结构损伤进展，验证了IL-6信号通路在该疾病中的关键作用。
3. **标题**: *Targeting interleukin-6 signaling in clinic: lessons from 20 years of anti-IL-6Rα therapy*
**作者**: Kishimoto T, et al.
**摘要**: 综述总结了IL-6Rα抗体(如托珠单抗)的研发历程，强调其通过阻断IL-6/STAT3通路治疗自身免疫病(如类风湿性关节炎、巨细胞动脉炎)及细胞因子风暴的机制，同时探讨了长期用药的安全性及耐药性问题。
---
以上研究涵盖临床应用、机制探索及疗效综述，反映了IL-6Rα抗体在多种疾病中的治疗价值。
Interleukin-6 receptor alpha (IL-6Rα) is a critical component of the IL-6 signaling pathway, which regulates immune responses, inflammation, and hematopoiesis. IL-6 binds to IL-6Rα, forming a complex with the signal-transducing protein gp130 to activate downstream JAK-STAT pathways, driving pro-inflammatory and regenerative processes. Dysregulated IL-6 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancer, making IL-6Rα a therapeutic target.
IL-6Rα-blocking antibodies, such as tocilizumab and sarilumab, are monoclonal antibodies designed to inhibit IL-6-mediated inflammation. These agents bind to membrane-bound or soluble IL-6Rα, preventing IL-6 from interacting with its receptor and interrupting downstream signaling. Approved for conditions like rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome (CRS), they effectively reduce inflammation and disease progression. Notably, tocilizumab gained attention during the COVID-19 pandemic for mitigating severe CRS in critically ill patients.
Despite their efficacy, IL-6Rα antibodies may increase infection risk due to immunosuppression. Other side effects include gastrointestinal perforation and altered lipid profiles. Research continues to explore their potential in other IL-6-driven diseases, such as lupus and certain cancers. Overall, IL-6Rα antibodies represent a cornerstone in targeted biologic therapy, balancing potent anti-inflammatory effects with manageable safety profiles.
×
